TrialJournal of diabetes investigation2020

Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.

Kohei Kaku et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.